The Group's principal activity is the development of humanized monoclonal antibodies for the treatment of diseases. The key areas of disease focus include oncology and inflammatory and autoimmune diseases. It has several humanized antibodies in clinical development for inflammatory bowel disease, psoriasis and asthma. The Group has licensed certain rights to first humanized antibody product, Zenpax to Hoffmann-La Roche Inc and its affiliates, which markets it for the prevention of kidney transplant rejection. The Groups Registered Trademarks are Protein Design Labs, Nuvion and Humanizing Science.
Alacra Alerts:
Receive alerts on the latest reports on PDL BioPharma, Inc.
Subscribe to Alacra Alerts via RSS and never miss the latest research on your favorite companies. Just click the images above to add the feed directly to your favorite newsreader.
